logo-loader
viewPolarean Imaging PLC

Full interview: Polarean Imaging achieves positive phase III results in two clinical trials

Polarean Imaging PLC (LON:POLX) CEO Richard Hullihen tells Proactive its two phase III clinical trials have 'demonstrated handily' that its technology allows doctors and surgeons to visualize aspects of lung function that have gone undetected using traditional magnetic resonances imaging (MRI) techniques. Hullihen says Polarean expects to submit a new drug application (NDA) for its drug/device in the third quarter, after a pre-NDA meeting with the FDA.

Quick facts: Polarean Imaging PLC

Price: 29 GBX

AIM:POLX
Market: AIM
Market Cap: £33.19 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: Polarean Imaging reports Phase III success for its lung...

Headlines from the Proactive UK newsroom. Polarean Imaging (LON:POLX) has received positive results from Phase III Clinical Trials of its lung scanning technology. Both trials met their primary endpoints. An application for US approval will be made in the autumn. Internet domain name...

2 weeks, 5 days ago

2 min read